Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Artificial tear Clear all
Recruiting No phase listed Observational

FX Shoulder Prospective Clinical Study

NCT06078865
View directory record Official record
Conditions
Osteoarthritis Shoulder, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Fracture, Shoulder
Interventions
FX Artificial Shoulder Prosthesis
Device
Lead sponsor
FX Shoulder Solutions
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
4
States / cities
Gilbert, Arizona • Marietta, Ohio • Wakefield, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 29, 2026, 5:05 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Treating Meibomian Gland Disease in a Pediatric Population

NCT07229001
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Disease
Interventions
Low level light treatment, warm compress and artificial tear
Other
Lead sponsor
Illinois College of Optometry
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

NCT07109869
View directory record Official record
Conditions
Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Interventions
Boric acid, Placebo
Drug · Other
Lead sponsor
pH-D Feminine Health LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Huntington Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 29, 2026, 5:05 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
View directory record Official record
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

NCT02939547
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 29, 2026, 5:05 PM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 29, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

NCT07471048
View directory record Official record
Conditions
Psoriasis
Interventions
Oral supplement containing 200mg Magnolia officinalis bark extract, Placebo
Dietary Supplement
Lead sponsor
Sirt3 LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 29, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Next-generation Probiotic, Veillonella Atypica FB0054 vs Placebo

NCT06141343
View directory record Official record
Conditions
Fatigue
Interventions
Veillonella atypica FB0054, Placebo
Dietary Supplement · Other
Lead sponsor
FitBiomics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Acute Comfort and Blur of Systane Ultra and Systane

NCT00748865
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Systane Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 29, 2026, 5:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 29, 2026, 5:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Interventions
Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

NCT04302896
View directory record Official record
Conditions
Medication Adherence, HIV
Interventions
dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
Drug
Lead sponsor
Rhonda Brand
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

NCT02925546
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Reducing Adenoviral Patient Infected Days

NCT02472223
View directory record Official record
Conditions
Conjunctivitis, Adenoviral Conjunctivitis
Interventions
Betadine 5%, Artificial Tears
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

NCT01007253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
PL nasal spray, fluticasone furoate (FF), PL eye drops, olopatadine (OLO)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

NCT00514852
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops

NCT05814367
View directory record Official record
Conditions
Visual Acuity
Interventions
Blink® Tears eye drops in a multidose bottle, Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
Drug
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Jacksonville, Florida • Maitland, Florida • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability

NCT01013077
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Optive, Soothe, New Emulsion, Soothe, New Emulsion, Optive, New Emulsion, Optive, Soothe
Other
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 29, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

NCT05999630
View directory record Official record
Conditions
Nasolacrimal Duct Obstruction, Thyroid Cancer
Interventions
Artificial Tears Methylcellulose
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 29, 2026, 5:05 PM EDT
Terminated Phase 4 Interventional Results available

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

NCT00553735
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine A 0.05%, Arificial Tear
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT00845299
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost punctal plug, artificial tears preserved with Benzalkonium Chloride
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Sep 29, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Envarsus in Delayed Graft Function (E-DGF)

NCT03864926
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 29, 2026, 5:05 PM EDT